System to Detect Cardiac Ischemia

The study involved 900 patients referred for myocardial perfusion imaging by single photon emission computed tomography (SPECT). The results indicated that the HyperQ analysis significantly improved the diagnostic ability of the stress test, reaching a sensitivity of 78% and specificity of 86%.

The HyperQ stress system uses sophisticated analysis of the ECG signal to provide a reliable measure for cardiac ischemia, based on the high-frequency components of the ECG. The system has been cleared by the U.S. Food and Drug Administration (FDA) and has received the CE Mark.

"The technology developed by BSP to extract the HyperQ signal can be integrated within a wide range of clinical systems, offering unmatched detection capabilities for ischemic conditions,” said Dr. Amir Beker, founder and CEO of Biological Signal Processing Ltd. (BSP, Tel Aviv, Israel), which developed the HyperQ system. The company was founded in 2000 by signal-processing experts, biomedical engineers, and clinicians. The company has been awarded a large grant by the Office of the Chief Scientist (OCS) of the Ministry of Industry and Trade in Israel for the development of BSP's next product, the HyperQ Rest Monitor.




Related Links:
BSP